Cargando…
FRI096 Efficacy Of Pemafibrate In Patients With Dyslipidemia: A Systematic Review And Meta - Analysis Of Randomized Controlled Trials
Disclosure: C.A. Balieiro: None. N.R. Nakajima: None. M.M. Gobbo: None. B.A. Gonçalves: None. N.D. Peixoto: None. E.T. Sirena: None. M.B. Moreira: None. In individuals with dyslipidemia, which is a well-known risk factor for cardiovascular events, pemafibrate may improve lipid abnormalities. We aime...
Autores principales: | Caroline Cristine, Almeida Balieiro, Romero Nakajima, Noah, Mizuhira Gobbo, Marcela, Assunes Gonçalves, Beatriz Polachini, do Amaral Peixoto, Natália Araujo, Teixeira Sirena, Eduardo Cesar, Barbosa Moreira, Matheus José |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10555419/ http://dx.doi.org/10.1210/jendso/bvad114.610 |
Ejemplares similares
-
Efficacy and safety of pemafibrate administration in patients with dyslipidemia: a systematic review and meta-analysis
por: Ida, Satoshi, et al.
Publicado: (2019) -
Clinical Applications of a Novel Selective PPARα Modulator, Pemafibrate, in Dyslipidemia and Metabolic Diseases
por: Yamashita, Shizuya, et al.
Publicado: (2019) -
Novel Selective PPARα Modulator Pemafibrate for Dyslipidemia, Nonalcoholic Fatty Liver Disease (NAFLD), and Atherosclerosis †
por: Yamashita, Shizuya, et al.
Publicado: (2023) -
096th LHCC Meeting
Publicado: (2008) -
O096: Care of patients with tracheostomy
por: Abraham, M
Publicado: (2013)